The Trump administration is redoubling its efforts to phase out animal testing in drug development and seeking to develop new biotechnology methods instead to spur innovation in the pharmaceutical market. 

The Food and Drug Administration and the National Institutes of Health launched parallel initiatives to help pharmaceutical companies implement new approach methodologies during the initial stages of drug development as an alternative to animal testing, which has drawn criticism from animal rights groups.